CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE

Post-LOE

betamethasone dipropionate; calcipotriene

Design Pharmaceuticals

ANDATOPICALSUSPENSION

Approved

Sep 2020

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE (betamethasone dipropionate; calcipotriene) by Design Pharmaceuticals is [see ] . Approved for psoriasis. First approved in 2020.

Drug data last refreshed 20h ago

Mechanism of Action

[see ] . Betamethasone dipropionate is a corticosteroid. Corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action for the treatment of tinea pedis, tinea cruris and tinea corporis is unknown.

Indications (1)

psoriasis

Company

Worked on CALCIPOTRIENE AND BETHAMETHASONE DIPROPIONATE at Design Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.